Bionor is a leading biotech company advancing a potential first therapeutic vaccine towards a functional cure for HIV

Latest news

Hide mandatory notifications of trade

Share capital increase registered

Financial .2015

(Oslo, 17 August 2015) With reference to the announcement made on 23 June 2015 regarding issuance of shares to members of the Board of Directors of Bionor as resolved by the Annual General Meeting on 13 May 2015, the share capital increase has now been registered in the Companies Register.

Bionor announces option issue to key employees

Financial .2015

(Oslo, Norway, 12 August 2015) The Board of Directors of Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has approved an updated option program for the next four year period, pending the continuing support of the shareholders through yearly grants of authorizations for share issues under the company’s incentive program.

H1 2015 Interim Financial Report

Financial .2015

Bionor Pharma ASA
Interim Financial Report
1 January – 30 June 2015
Unaudited

Oslo, 12 August 2015

Share capital increase registered

Financial .2015

(Oslo, 17 August 2015) With reference to the announcement made on 23 June 2015 regarding issuance of shares to members of the Board of Directors of Bionor as resolved by the Annual General Meeting on 13 May 2015, the share capital increase has now been registered in the Companies Register.

Bionor announces option issue to key employees

Financial .2015

(Oslo, Norway, 12 August 2015) The Board of Directors of Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has approved an updated option program for the next four year period, pending the continuing support of the shareholders through yearly grants of authorizations for share issues under the company’s incentive program.

H1 2015 Interim Financial Report

Financial .2015

Bionor Pharma ASA
Interim Financial Report
1 January – 30 June 2015
Unaudited

Oslo, 12 August 2015

Go to news section

Featured content